Inspired by the acquisition of Cord Blood Registry by AMAG Pharmaceuticals for $700M in June of 2015, this post considers five cord blood investors that are impacting the global marketplace. It includes traditional investments, acquisitions, and contributions from wealthy founders. If you are operating within the cord blood industry, you need to know these market investors. [Read more…]
Hematopoietic Stem Cells (HSCs)
Should Stem Cells Be Regulated As Drugs?
Should stem cells be regulated by the U.S. Food and Drug Administration (FDA) as drugs? This is a complex question and one that the FDA has continued to refine over the past several years.
FDA Regulation of Stem Cells
In the United States, cellular therapies are regulated by the FDA’s Office of Cellular, Tissue, and Gene Therapies (OCTGT) within the FDA Center for Biologics Evaluation and Research (CBER). [Read more…]
Growing Stem Cells in Suspension Bioreactors with Dr. Angel of Accellta
Dr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta, has more than 30 years of experience guiding the business development efforts of new and established companies across the Israeli pharmaceutical industry. Dr. Angel was formerly Vice President of R&D at Proteologics Ltd. and at D-Pharm Biopharmaceuticals. Before those positions, he served as the head of pharmacology in Synthelabo (now Sanofi) where he launched blockbuster drugs such as Xatral, Ambien and Mizollen into the marketplace. [Read more…]
PLX-R18 Supports Hematological Recovery After Low Radiation Exposure
-
Findings pave the way to potentially use PLX-R18 to support hematological recovery following radiotherapy or chemotherapy
-
Data focuses on 12 additional NHPs that were exposed to lower radiation levels
HAIFA, ISRAEL, JULY 26, 2017— Pluristem Therapeutics Inc. (NASDAQ: PSTI) (TASE: PSTI), a leading developer of placenta-based cell therapy products, today presented new data at the RITN (Radiation Injury Treatment Network) conference from a recent study evaluating PLX-R18 as a treatment for Acute Radiation Syndrome (ARS). [Read more…]
These 4 Companies Dominate the Cord Blood Processing Industry
This article identifies four key processing technologies that are utilized by cord blood banks worldwide and the companies responsible for developing each one. Automated processing systems have many benefits, including speed, processing efficiency, and cost-savings. However, automated processing systems have not always dominated the cord blood banking industry.
Cell Processing in the Cord Banking Industry
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 28
- Next Page »